期刊文献+

影响进展期胃癌预后的多因素分析 被引量:12

Multivariate analysis of prognosis in patients with advanced gastric cancer
下载PDF
导出
摘要 目的探讨包括临床病理特征、肿瘤标志物水平、炎性指标在内的23项指标对判断进展期胃癌预后的价值。方法回顾性分析我院248例Ⅲ~Ⅳ期胃癌术后患者的病例资料。采用Kaplan-Meier法计算生存率,用Log-rank法进行单因素分析,Cox风险比例模型进行多因素分析。结果单因素分析显示肿瘤大小、T分期、N分期、Lauren分型、脉管浸润、手术方式、癌胚抗原(CEA)、糖类抗原(CA)724、CA199、CA125、Glasgow预后评分(GPS)、中性粒细胞淋巴细胞比率(NLR)、血小板淋巴细胞比率(PLR)与进展期胃癌预后有关。多因素分析显示姑息性手术、T4b、CEA升高、CA199升高是判断进展期胃癌预后的独立危险因素。结论姑息性手术、T4b、CEA升高、CA199升高是影响进展期胃癌术后患者预后的独立危险因素。 Objective To investigate the value of clinicopathologic characteristics,serum tumor markers and inflammatory factors in judging the prognosis of advanced gastric cancer. Methods Two hundred and forty-eight gastric cancer patients with stageⅢ-Ⅳ undergoing operation in Nanjing Drum Hospital between 2008 and 2013 were included in this study. The postoperative survival rate was calculated by Kaplan-Meier method. Univariate analysis of prognosis were used by Log-rank method. Multivariable analysis of prognosis was used by Cox proportional hazad regression model. Results In univariate analysis,tumor size,T staging,N staging,Lauren classification,vascular invasion,surgical modalities,carcinoembryonic antigen( CEA),carbohydrate antigen( CA) 724,CA199,CA125,Glasgow prognostic score( GPS),neutrophil to lymphocyte ratio( NLR) and platelet to lymphocyte ratio( PLR) were associated with overall survival in patients with advanced gastric cancer. Multivariate analysis revealed that palliative surgery,stage of T4b,CEA,CA199 were independent risk factors of poor prognosis. Conclusion Palliative surgery,stage of T4b,CEA,CA199 are independent risk factors of patients with advanced gastric cancer.
出处 《临床肿瘤学杂志》 CAS 2014年第6期524-529,共6页 Chinese Clinical Oncology
关键词 胃癌 临床病理特征 肿瘤标志物 炎性指标 预后 Gastric cancer Clinicopathologic characteristics Tumor markers Inflammatory factors Prognosis
  • 相关文献

参考文献18

  • 1Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in ad- vanced gastric cancer: a systematic review and meta-analysis based on aggregate data[J]. J Clin Oncol, 2006, 13(18) : 2903 - 2909.
  • 2Pasini F, Fraecon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer[ J]. Anticancer Res, 2011, 13(10) : 3543-3554.
  • 3Yokota T, lshiyama S, Saito T, et al. Lymphnode metastasis as a significant prognostic factor in gastric cancer: a multiplclogistic regression analysis [ J ]. So, and J Gastroentcrol, 2004, 39 (4) :380-384.
  • 4Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large Uspopulation database[ J]. J Clin Oncol, 2005, 23(28) : 7114-7124.
  • 5Mohri Y, Tanaka K, Ohi M, et al. Prognostic significance of host-and tumor-related factors in patients with gastric cancer[J]. World J Surg, 2010, 34(10) : 285-290.
  • 6Jun KH, Jung H, Baek JM, et al. Does tumor size have an impact on gastric cancer? A single institute experience[ J]. Lan- genberk Arch Surg, 2009, 394(4) : 631-635.
  • 7Dutta S, Crumley AB, Fullarton GM, et al. Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer [J]. Am J Surg, 2012, 204(3) : 294-299.
  • 8Jeong JH, Lim SM, Yun JY, et al. Comparison of two inflamma- tion-based prognostic ccores in patients with unresectable advanced gastric cancer[ J]. Oncology, 2012, 83 (5) : 292-299.
  • 9Suee Lee, Sung Yong Oh, Sung Hyun Kim, et al. Prognostic sig- nificance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy[J]. BMC Cancer, 2013, 22( 13): 350.
  • 10National comprehensive cancer network. NCCN clinical practice guidelines in oncology : gastric cancer, version 2. 2013 [ EB/OL]. 2013 [ 2014-02-25]. http://www, nccn. org/professionals/ physician_gls/f_guidelines, asp.

二级参考文献15

  • 1Trumper M, Ross PJ, Cunningham D, et al.Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials[J]. EurJ Cancer, 2006,42(7) :827-834.
  • 2Lu Z, Lu M, Zhang X, et al. Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments[J]. Clin Transl Oncol,2013, 15( 5) :376-383.
  • 3Bilir C, Engin H, Bakkal BH, et al. Chemotherapy in elderly patients with metastatic gastric cancer; a single Turkish cancer center experience[J]. Med Glas (Zenica), 2013, 10 ( 2) : 298 -303.
  • 4Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2010, 17 (3) : CD004064.
  • 5Koizumi W, Narahara H, Hara T, et al. S" 1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase m trial[J]. Lancet Oncol , 2008 , 9 ( 3) : 215 -221.
  • 6Tsushima T, Hironaka S, Boku N, et a1. Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer[J]. IntJ Clin Oncol , 2013, 18( 1) : 10-16.
  • 7LeeJL, Kang YK, Kang HJ, et a1. A randomised multicentre phase n trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer] J J. BrJ Cancer, 2008 ,99( 4) :584-590.
  • 8Tsushima T, Hironaka S, Boku N, et al. Safety and efficacy of S- 1 monotherapy in elderly patients with advanced gastric cancer[J]. Gastric Cancer, 2010,13(4) :245-250.
  • 9Kim HS, Kim HJ, Kim SY, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis] 1]. Ann Oncol ,2013 ,24(11) : 2850-2854.
  • 10Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data[J] .J Clin Oncol , 2004,22( 12) :2395-2403.

共引文献8

同被引文献108

  • 1李华,路平,刘彩刚,司荣祥,关华鹤,徐惠绵.青年早期胃癌临床病理特征及预后因素探讨[J].中国普通外科杂志,2007,16(9):910-912. 被引量:13
  • 2周吉昌.《实用肿瘤内科学》[M].2版.人民卫生出版社,2011.
  • 3Miles K A, Hayball M, Dixon A K. Colour perfusion imaging: a new application of computed tomography[J]. Lancet 1991,337 (8742) =643--645.
  • 4. RazekA A,Tawfik A M,Elsorogy g G,e* al. Perfusion CT of head and neck cancer[J]. Eur J Radiol,2014,83(3) :537--544.
  • 5Gibaldi A, Barone D, Gavelli G, et al. Effects of guided random sampling of TCCs on blood flow values in CT perfusion studies of lung tumors[J]. Acad Radiol,2015,22(1) :58--69.
  • 6Guo M, Yu Y. Application of 128 slice 4D CT whole liver perfusion imaging in hepatic tumor[J]. Cell Biochem Biophys, 2014,70 ( 1 ) : 173--178.
  • 7Martin L H, Eva F,Carsten L, et al. Computed Tomography (CT) perfusion as an early predictive marker or treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer-- a prospective study[J]. PLoS one, 2014, 9 (5) :e97605.
  • 8Goseki N,Takizawa T,Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma[J]. Gut, 1992,33 (5):606 -612.
  • 9van der Schaaf MK,Tilanus HW,van Lanschot JJ,et al. The influence of preoperative weight loss on the postoperative course after esophageal cancer resection[J]. J Thorac Cardiovasc Surg,2014,147(1):490-495.
  • 10Edge SB,Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17 (6):1471-1474.

引证文献12

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部